A Normal DXA Two Years Ago Does NOT Rule Out Osteoporosis After a Low-Energy Fracture
In a postmenopausal woman who sustained a low-energy fracture, treatment should be initiated regardless of a normal DXA scan performed two years ago, because the fracture itself establishes the diagnosis of osteoporosis and indicates high fracture risk. 1, 2, 3
Why the Previous Normal DXA Doesn't Change Management
The presence of a fragility fracture fundamentally changes the clinical picture:
Osteoporosis can be diagnosed based on a fragility fracture alone, even with normal bone mineral density. This is explicitly stated in multiple guidelines 2, 3. The T-score threshold of -2.5 is just one diagnostic criterion—not the only one.
A fracture from low-energy trauma (falling from standing height or less) is itself diagnostic of osteoporosis and indicates the bone quality is compromised regardless of what the density measurement shows 1, 2.
Bone density can change over two years, particularly in postmenopausal women who may experience accelerated bone loss. The previous normal scan is now outdated 2.
The Critical Concept: Fracture Risk vs. Bone Density
Guidelines emphasize that treatment decisions should be based on fracture risk, not just BMD numbers 4, 2:
- Recent fractures (within the past 2 years) are among the strongest predictors of imminent future fractures 4
- Women with a history of fragility fracture have significantly elevated risk of subsequent fractures, with rates around 8-9% within 2 years 5
- Treatment should be considered in women who have had a low-trauma fracture, even if DXA does not indicate osteoporosis 1
Recommended Management Approach
1. Initiate Pharmacologic Treatment Immediately
Do not wait for a repeat DXA scan to start treatment. The fracture itself is sufficient indication 1, 2, 3:
- First-line options: Bisphosphonates (alendronate, risedronate, zoledronic acid), denosumab 2
- Consider anabolic agents (teriparatide, abaloparatide, romosozumab) if this is a recent fracture (within 12 months), multiple fractures, or vertebral fracture, as these patients are at "very high risk" 2
2. Obtain a New DXA Scan
While treatment shouldn't be delayed, obtain a current baseline DXA 2:
- This establishes a new baseline for monitoring treatment response
- Helps stratify ongoing fracture risk
- May reveal significant bone loss since the previous scan
- Repeat DXA every 1-2 years while on treatment 2
3. Evaluate for Secondary Causes
Since she fractured despite a previously normal DXA, investigate potential accelerated bone loss 2, 3:
- Complete metabolic panel (calcium, phosphorus, alkaline phosphatase)
- 25-hydroxyvitamin D level
- Thyroid function tests
- Consider: celiac screening, parathyroid hormone, 24-hour urine calcium
- Review medications that may cause bone loss (glucocorticoids, aromatase inhibitors, anticonvulsants, proton pump inhibitors)
4. Non-Pharmacologic Measures
Implement immediately alongside medication 4, 1, 2:
- Calcium 1,000-1,200 mg daily
- Vitamin D 600-800 IU daily (target level >30 ng/mL)
- Weight-bearing and resistance exercises 3-5 times weekly
- Balance training 2-3 times weekly to prevent falls
- Smoking cessation and alcohol limitation
Common Pitfalls to Avoid
Pitfall #1: Waiting for a repeat DXA before treating
- The fracture is the event that matters most. Delaying treatment increases the risk of additional fractures during the highest-risk period immediately post-fracture 4.
Pitfall #2: Assuming the old normal DXA means "no osteoporosis"
- Bone density is only one component of bone strength. Microarchitecture, bone turnover, and accumulated microdamage all contribute to fracture risk and aren't captured by DXA 2.
Pitfall #3: Underestimating fracture risk in "borderline" cases
- Any fragility fracture in a postmenopausal woman warrants treatment 1, 2. The previous normal DXA actually makes this case more concerning—it suggests rapid bone loss or poor bone quality despite adequate density.
Duration and Monitoring
- Continue treatment for at least 3-5 years initially 4, 2
- Reassess fracture risk at that point using repeat DXA and clinical factors
- If using bisphosphonates and risk becomes low-moderate, consider a drug holiday after 5 years (oral) or 3 years (zoledronic acid) 4, 2
- However, given she already fractured, she likely remains high risk and should continue therapy 4, 2
- If using denosumab or anabolic agents, do not take a drug holiday—transition to bisphosphonate if stopping 2
Bottom Line
The fragility fracture trumps the previous normal DXA. This patient has proven bone fragility through clinical events, which is more predictive of future fractures than any density measurement. Treat aggressively now to prevent the next fracture, which statistically is most likely to occur within the next 1-2 years 4, 5.